Track topics on Twitter Track topics that are important to you
Basilea Pharmaceutica International plans to develop and commercialize ArQule’s Phase III intrahepatic cholangiocarcinoma (iCCA) candidate derazantinib (ARQ087) worldwide except greater China, through an exclusive licensing agreement that ArQule said today could generate for it up to $336 million-plus. Derazantinib is a pan-fibroblast growth factor receptor (FGFR) inhibitor now in a registrational trial ( NCT03230318 ) in patients with FGFR2 fusion-positive inoperable or advanced iCCA, a form of biliary tract cancer, in the U.S. as well as Canada and Europe. The primary endpoint is anticancer activity measured by Objective Response Rate. Under the companies’ agreement, ArQule said, Basilea plans to continue the estimated 100-patient trial as well as further development of derazantinib in iCCA and other tumor types with FGFR dysregulation. Derazantinib is in two additional clinical studies that were active but not recruiting patients as of January 12: A Phase II trial in patients with iCCA ...NEXT ARTICLE
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...